Table 4.
Cox regression
| Patient characteristics | Hazard ratio (95% confidence interval)
|
||
|---|---|---|---|
| Overall patients (n=2,537) | Biologic-naïve patients (n=272) | Biologic-continuing patients (n=2,265) | |
| Age | |||
| ≤60 years | Reference | Reference | Reference |
| 61–75 years | 0.88 (0.67–1.05) | 1.05 (0.29–3.80) | 0.83 (0.66–1.04) |
| >75 years | 0.60 (0.40–0.91) | 1.83 (0.34–9.95) | 0.56 (0.37–0.86) |
| Sex | |||
| Male | Reference | Reference | Reference |
| Female | 1.03 (0.79–1.34) | 0.49 (0.14–1.73) | 1.05 (0.80–1.38) |
| CCI score | |||
| ≤2 | Reference | Reference | Reference |
| 3–5 | 1.33 (1.03–1.70) | 5.29 (0.94–41.21) | 1.26 (0.98–1.61) |
| >5 | 1.89 (1.40–2.57) | 1.87×109 | 1.93 (1.42–2.62) |
| Biologic agent | |||
| Etanercept | Reference | Reference | Reference |
| Adalimumab | 0.76 (0.57–1.02) | 0.30 (0.03–2.68) | 0.78 (0.58–1.05) |
| Infliximab | 0.32 (0.22–0.45) | 0.23 (0.04–1.23) | 0.32 (0.22–0.46) |
| Golimumab | 0.46 (0.24–0.87) | 9.59×10−19 | 0.52 (0.27–0.97) |
| Tocilizumab | 0.51 (0.37–0.71) | 0.29 (0.05–1.53) | 0.52 (0.37–0.72) |
| Abatacept | 0.20 (0.10–0.44) | 0.49 (0.09–2.67) | 0.16 (0.07–0.39) |
| Naïve | |||
| Naïve patients | Reference | ||
| Continuing biologic patients | 3.01 (1.69–5.38) | ||
| LR χ2(12)=119.90 | LR χ2(12)=18.62 | LR χ2(12)=92.01 | |
| Prob > χ2=0.0000 | Prob > χ2=0.0286 | Prob > χ2=0.0000 | |
Abbreviations: CCI, Charlson Comorbidity Index; LR (χ2), likelihood ratio chi-square; Prob, probability.